138 related articles for article (PubMed ID: 36476926)
1. [Clinical Application and Research Progress of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Zhang HY; Yang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1917-1921. PubMed ID: 36476926
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Application of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review].
Chen XF; Wang M; Zhang F; Li JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):638-642. PubMed ID: 33812444
[TBL] [Abstract][Full Text] [Related]
5. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy in diffuse large B-cell lymphoma: utility in cell origin determination and survival prediction in Chinese patients.
Li M; Ding N; Mi L; Shi Y; Du X; Yi Y; Yang L; Liu W; Zhu J
Leuk Lymphoma; 2022 Mar; 63(3):608-617. PubMed ID: 34751093
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
[TBL] [Abstract][Full Text] [Related]
8. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Scherer F; Kurtz DM; Newman AM; Stehr H; Craig AF; Esfahani MS; Lovejoy AF; Chabon JJ; Klass DM; Liu CL; Zhou L; Glover C; Visser BC; Poultsides GA; Advani RH; Maeda LS; Gupta NK; Levy R; Ohgami RS; Kunder CA; Diehn M; Alizadeh AA
Sci Transl Med; 2016 Nov; 8(364):364ra155. PubMed ID: 27831904
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis.
Yao L; Xu H; Wo J; Zhao M; Liu Z; Dong T; Xiao S
Clin Exp Med; 2022 Feb; 22(1):1-7. PubMed ID: 33990849
[TBL] [Abstract][Full Text] [Related]
10. Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
Fu H; Shen J; Zhou H; Zhang F; Li H; Ma Z; Huang W; Chen L; Chen Y; Liu T
Eur J Haematol; 2022 Apr; 108(4):298-309. PubMed ID: 34997652
[TBL] [Abstract][Full Text] [Related]
11. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
[TBL] [Abstract][Full Text] [Related]
12. Updates on Circulating Tumor DNA Assessment in Lymphoma.
Darrah JM; Herrera AF
Curr Hematol Malig Rep; 2018 Oct; 13(5):348-355. PubMed ID: 30136210
[TBL] [Abstract][Full Text] [Related]
13. Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA.
Herrera AF; Tracy S; Croft B; Opat S; Ray J; Lovejoy AF; Musick L; Paulson JN; Sehn LH; Jiang Y
Blood Adv; 2022 Mar; 6(6):1651-1660. PubMed ID: 35086141
[TBL] [Abstract][Full Text] [Related]
14. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
[TBL] [Abstract][Full Text] [Related]
15. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
Camus V; Viennot M; Lévêque E; Viailly PJ; Tonnelet D; Veresezan EL; Drieux F; Etancelin P; Dubois S; Stamatoullas A; Tilly H; Bohers E; Jardin F
Leuk Lymphoma; 2022 Apr; 63(4):834-844. PubMed ID: 35075971
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
18. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
[TBL] [Abstract][Full Text] [Related]
20. Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.
Huet S; Salles G
JCO Oncol Pract; 2020 Sep; 16(9):561-568. PubMed ID: 32421389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
